Revenue Breakdown
Composition ()
No data
Revenue Streams
Alnylam Pharmaceuticals Inc (ALNY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is AMVUTTRA, accounting for 54.9% of total sales, equivalent to $685.30M. Other significant revenue streams include Regeneron Pharmaceuticals and GIVLAARI. Understanding this composition is critical for investors evaluating how ALNY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Alnylam Pharmaceuticals Inc maintains a gross margin of 75.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.01%, while the net margin is 16.99%. These profitability ratios, combined with a Return on Equity (ROE) of 73.28%, provide a clear picture of how effectively ALNY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ALNY competes directly with industry leaders such as HLN and ZTS. With a market capitalization of $43.11B, it holds a significant position in the sector. When comparing efficiency, ALNY's gross margin of 75.60% stands against HLN's 64.19% and ZTS's 68.96%. Such benchmarking helps identify whether Alnylam Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
